Publicaciones en colaboración con investigadores/as de University of Virginia (7)

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

2019

  1. Author Correction: ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development (Nature Immunology, (2019), 20, 11, (1409-1413), 10.1038/s41590-019-0503-1)

    Nature Immunology

  2. ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

    Nature Immunology

2009

  1. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome

    Journal of Cell Biology, Vol. 187, Núm. 7, pp. 1083-1099

1998

  1. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions

    Journal of Clinical Investigation, Vol. 102, Núm. 6, pp. 1239-1248

1993

  1. Brain-derived neurotrophic factor and neurotrophin-3 support the survival and neuritogenesis response of developing cochleovestibular ganglion neurons

    Developmental Biology, Vol. 159, Núm. 1, pp. 266-275

1991

  1. Glycosyl-phosphatidylmpsitol/Hiositol phosphoglycan: A signaling system for the low-affinity nerve growth factor receptor

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 88, Núm. 18, pp. 8016-8019